Literature DB >> 20189314

Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression.

Jack R Cornelius1, Howard J Aizenstein, Ahmad R Hariri.   

Abstract

Phan et al. (2008) recently reported that an acute dose of oral THC is associated with a decrease in threat-related amygdala reactivity during a social threat stimulus task. However, to date, those findings have not been replicated, and have not been extended to clinical studies involving smoked rather than oral cannabis. In this study, we hypothesized that level of cannabis smoked by participants in our treatment study would be inversely related to the level of threat-related amygdala reactivity. Subjects were recruited from among participants in our double-blind, placebo-controlled trial of fluoxetine in comorbid youth with cannabis dependence/major depression. The threat-related amygdala reactivity task used by Hariri et al. (2009) was completed during BOLD fMRI scans at study baseline and then again 12 weeks later at the end of the trial. Data are available from six subjects with pre-and post-treatment fMRI data. During the course of the study, five of the six subjects demonstrated a decrease in their level of cannabis use, with a mean decrease of 64%, and those persons all demonstrated an increase in their level of amygdala reactivity. One subject demonstrated an increase in their level of cannabis use (a 79% increase) during the treatment trial, and that person demonstrated a decrease in their level of amygdala reactivity. Thus, a higher level of cannabis use was consistently associated with a lower level of amygdala reactivity across all subjects (matched pairs t = 2.70, df = 5, p < 0.05, two-tailed). These findings are consistent with the reports by Phan et al. (2008) and Hariri et al. (2009) suggesting that cannabinoids have an inhibitory effect on threat-related amygdala reactivity. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189314      PMCID: PMC2841401          DOI: 10.1016/j.addbeh.2010.02.004

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  10 in total

1.  Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study.

Authors:  Y I Sheline; D M Barch; J M Donnelly; J M Ollinger; A Z Snyder; M A Mintun
Journal:  Biol Psychiatry       Date:  2001-11-01       Impact factor: 13.382

Review 2.  Involvement of the endocannabinoid system in drug addiction.

Authors:  Rafael Maldonado; Olga Valverde; Fernando Berrendero
Journal:  Trends Neurosci       Date:  2006-02-17       Impact factor: 13.837

Review 3.  Endocannabinoid system and stress and anxiety responses.

Authors:  M P Viveros; Eva M Marco; Sandra E File
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

Review 4.  Neuroimaging abnormalities in the amygdala in mood disorders.

Authors:  Wayne C Drevets
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

5.  Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study.

Authors:  Cynthia H Y Fu; Steven C R Williams; Anthony J Cleare; Michael J Brammer; Nicholas D Walsh; Jieun Kim; Chris M Andrew; Emilio Merlo Pich; Pauline M Williams; Laurence J Reed; Martina T Mitterschiffthaler; John Suckling; Edward T Bullmore
Journal:  Arch Gen Psychiatry       Date:  2004-09

6.  Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system.

Authors:  Simona Perra; Giuliano Pillolla; Antonio Luchicchi; Marco Pistis
Journal:  Alcohol Clin Exp Res       Date:  2008-01-22       Impact factor: 3.455

7.  Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function.

Authors:  Ahmad R Hariri; Adam Gorka; Luke W Hyde; Mark Kimak; Indrani Halder; Francesca Ducci; Robert E Ferrell; David Goldman; Stephen B Manuck
Journal:  Biol Psychiatry       Date:  2008-12-21       Impact factor: 13.382

8.  Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.

Authors:  Jack R Cornelius; Tammy Chung; Christopher Martin; D Scott Wood; Duncan B Clark
Journal:  Addict Behav       Date:  2008-02-11       Impact factor: 3.913

9.  Cannabinoid modulation of amygdala reactivity to social signals of threat in humans.

Authors:  K Luan Phan; Mike Angstadt; Jamie Golden; Ikechukwu Onyewuenyi; Ana Popovska; Harriet de Wit
Journal:  J Neurosci       Date:  2008-03-05       Impact factor: 6.167

10.  Antidepressant drug treatment modifies the neural processing of nonconscious threat cues.

Authors:  Catherine J Harmer; Clare E Mackay; Catriona B Reid; Philip J Cowen; Guy M Goodwin
Journal:  Biol Psychiatry       Date:  2006-02-07       Impact factor: 13.382

  10 in total
  32 in total

1.  Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users.

Authors:  Joseph P Schacht; Kent E Hutchison; Francesca M Filbey
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect.

Authors:  Christine A Rabinak; Chandra Sekhar Sripada; Mike Angstadt; Harriet de Wit; K Luan Phan
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

3.  Paradoxical Decrease in Striatal Activation on an fMRI Reward Task Following Treatment in Youth with Co-morbid Cannabis Dependence/Major Depression.

Authors:  Jack R Cornelius; Howard J Aizenstein; Tammy A Chung; Antoine Douaihy; Jeanine Hayes; Dennis Daley; Ihsan M Salloum
Journal:  Adv Psychol Res       Date:  2013

4.  Blunted stress reactivity in chronic cannabis users.

Authors:  Carrie Cuttler; Alexander Spradlin; Amy T Nusbaum; Paul Whitney; John M Hinson; Ryan J McLaughlin
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

Review 5.  Neuroimaging Studies in Patients With Mental Disorder and Co-occurring Substance Use Disorder: Summary of Findings.

Authors:  Kaloyan Rumenov Stoychev
Journal:  Front Psychiatry       Date:  2019-10-23       Impact factor: 4.157

Review 6.  The underlying neurobiology of key functional domains in young people with mood and anxiety disorders: a systematic review.

Authors:  Frank Iorfino; Ian B Hickie; Rico S C Lee; Jim Lagopoulos; Daniel F Hermens
Journal:  BMC Psychiatry       Date:  2016-05-23       Impact factor: 3.630

7.  Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans.

Authors:  Christine A Rabinak; Mike Angstadt; Maryssa Lyons; Shoko Mori; Mohammed R Milad; Israel Liberzon; K Luan Phan
Journal:  Neurobiol Learn Mem       Date:  2013-09-19       Impact factor: 2.877

Review 8.  Interaction of Cannabis Use and Aging: From Molecule to Mind.

Authors:  Hye Bin Yoo; Jennifer DiMuzio; Francesca M Filbey
Journal:  J Dual Diagn       Date:  2019-09-30

9.  Gender effects on amygdala morphometry in adolescent marijuana users.

Authors:  Tim McQueeny; Claudia B Padula; Jenessa Price; Krista Lisdahl Medina; Patrick Logan; Susan F Tapert
Journal:  Behav Brain Res       Date:  2011-06-02       Impact factor: 3.332

10.  A preliminary examination of how serotonergic polymorphisms influence brain response following an adolescent cannabis intervention.

Authors:  Sarah W Feldstein Ewing; Hilary K Mead; Uma Yezhuvath; Sam Dewitt; Kent E Hutchison; Francesca M Filbey
Journal:  Psychiatry Res       Date:  2012-11-30       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.